In August 2025, Ohio Governor Mike DeWine called on the Ohio Board of Pharmacy (OBP) to designate all natural and synthetic kratom compounds as Schedule I drugs. This statement came just weeks after the U.S. Food and Drug Administration (FDA) announced their recommendation to place kratom compound 7-hydroxymitragynine (also referred to as 7-OH) products under Schedule I of the Controlled Substances Act (CSA). This page answers common questions about kratom and its compounds, details the regulatory efforts in Ohio and other states, and provides information on federal scheduling and public health information.

This page details the drug-related ballot initiatives that are up for a vote in the next election and tracks pending ballot initiatives that could impact the status of marijuana legalization. The page also provides a timeline of efforts to enact and implement marijuana reforms via the ballot box since 1996 as well as information on the results of ballot initiatives from recent years.